-
公开(公告)号:US20080221129A1
公开(公告)日:2008-09-11
申请号:US11825431
申请日:2007-07-06
申请人: Thomas Lundback , Isabel Climent-Johansson , Jan Vagberg , Auri Linden , Jonas Nilsson , Marie Wiik , Ulf Bremberg
发明人: Thomas Lundback , Isabel Climent-Johansson , Jan Vagberg , Auri Linden , Jonas Nilsson , Marie Wiik , Ulf Bremberg
IPC分类号: A61K31/519 , C07D487/04 , A61P9/00 , A61P3/04 , A61P25/00 , A61P17/00
CPC分类号: C07D487/04
摘要: The present invention relates to compounds of the formula (I): including pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers, and N-oxides thereof, said compounds being useful as inhibitors of stearoyl-CoA desaturase (SCD). The invention further relates to the use of compounds of the formula (I) for treatment of medical conditions in which the modulation of SCD activity is beneficial, such as cardiovascular diseases, obesity, non-insulin-dependent diabetes mellitus, hypertension, neurological diseases, immune disorders, cancer, essential fatty acid deficiency, acne, psoriasis, rosacea or other skin conditions.
摘要翻译: 本发明涉及式(I)化合物:其药学上可接受的盐,溶剂化物,水合物,几何异构体,互变异构体,旋光异构体及其N-氧化物,所述化合物可用作硬脂酰辅酶A去饱和酶(SCD) 。 本发明还涉及式(I)化合物用于治疗其中SCD活性调节有益的医学病症,例如心血管疾病,肥胖症,非胰岛素依赖性糖尿病,高血压,神经系统疾病, 免疫疾病,癌症,必需脂肪酸缺乏症,痤疮,牛皮癣,酒渣鼻或其他皮肤病症。
-
公开(公告)号:US20080255153A1
公开(公告)日:2008-10-16
申请号:US12079563
申请日:2008-03-27
申请人: Ulf Bremberg , Auri Linden , Thomas Lundback , Jonas Nilsson , Marie Wiik , Magnus Bergner , Peter Brandt , Kristin Hammer , Rune Ringom
发明人: Ulf Bremberg , Auri Linden , Thomas Lundback , Jonas Nilsson , Marie Wiik , Magnus Bergner , Peter Brandt , Kristin Hammer , Rune Ringom
IPC分类号: A61K31/519 , C07D487/04 , A61P9/00
CPC分类号: C07D487/04
摘要: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, which are useful as inhibitors of human stearoyl-CoA desaturase (SCD). The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment or prevention of medical conditions in which the modulation of SCD activity is beneficial, such as cardiovascular diseases, obesity, non-insulin-dependent diabetes mellitus, hypertension, metabolic syndrome, neurological diseases, immune disorders, cancer and various skin diseases.
摘要翻译: 本发明涉及可用作人硬脂酰辅酶A去饱和酶(SCD)抑制剂的式(I)化合物及其药学上可接受的盐。 本发明进一步涉及包含这些化合物的药物组合物和这些化合物用于治疗或预防SCD活性调节有益的医学病症的用途,例如心血管疾病,肥胖症,非胰岛素依赖性糖尿病, 高血压,代谢综合征,神经系统疾病,免疫疾病,癌症和各种皮肤疾病。
-
公开(公告)号:US20080039450A1
公开(公告)日:2008-02-14
申请号:US11821565
申请日:2007-06-21
申请人: Annika Jensen , Rune Ringom , Carmen Medina , John Vock , Marie Wiik , Tobias Koolmeister , Johan Angbrant , Martin Henriksson , Teresa Sandvall , Lori Sutin , Lars Johannson , Bjorn Nilsson
发明人: Annika Jensen , Rune Ringom , Carmen Medina , John Vock , Marie Wiik , Tobias Koolmeister , Johan Angbrant , Martin Henriksson , Teresa Sandvall , Lori Sutin , Lars Johannson , Bjorn Nilsson
IPC分类号: A61K31/5377 , A61K31/4439 , A61K31/496 , A61P25/00 , A61P3/00 , A61P9/00 , C07D401/04 , C07D403/10 , C07D405/04 , C07D417/12 , C07D413/14 , C07D413/10 , C07D405/12 , C07D403/12 , C07D401/14 , C07D241/20 , A61P35/00 , A61P29/00 , A61K31/541 , A61K31/4965
CPC分类号: C07D401/12 , C07D401/04 , C07D403/12 , C07D403/14 , C07D405/12 , C07D471/04
摘要: The present invention relates to compounds of the general formula I wherein X, Y, Z, A, Ar, R1, R2, R3, and R4 are as defined herein, which compounds are inhibitors of MNK2 and MNK1. The invention also relates to the use of the compounds in therapy, pharmaceutical compositions comprising the compounds, and the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of disorders related to undesired activity of MNK1 and/or MNK2 kinases.
摘要翻译: 本发明涉及通式I的化合物,其中X,Y,Z,A,Ar,R 1,R 2,R 3, >和R 4如本文所定义,这些化合物是MNK2和MNK1的抑制剂。 本发明还涉及化合物在治疗中的用途,包含该化合物的药物组合物,以及该化合物在制备用于预防和治疗与MNK1和/或MNK2激酶的不期望活性相关的疾病的药物中的用途。
-
-